Cargando…
1811. Impact of a one-time oritavancin infusion on hospital length of stay for uncomplicated skin and soft tissue infections
BACKGROUND: Oritavancin is a lipoglycopeptide antibiotic approved in the United States for the treatment of adults with skin and soft tissue infections (SSTIs). Given the extended half-life of this agent, a one-time intravenous (IV) infusion is adequate to treat SSTIs. This single IV dose provides a...
Autores principales: | Bremmer, Derek N, Alvarez, Gabriela, Buchanan, Carley, Carr, Dustin R, Shively, Nathan R, Moffa, Matthew A, Trienski, Tamara, Walsh, Thomas L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677577/ http://dx.doi.org/10.1093/ofid/ofad500.1640 |
Ejemplares similares
-
108. Efficacy of Dalbavancin Compared to Standard of Care for the Treatment of Osteomyelitis: A Retrospective Study
por: Cain, Alexander, et al.
Publicado: (2021) -
Analysis of a beta-lactam allergy assessment protocol challenging diverse reported allergies managed by an antimicrobial stewardship program
por: Jacobs, Max W., et al.
Publicado: (2023) -
Effectiveness of Dalbavancin Compared With Standard of Care for the Treatment of Osteomyelitis: A Real-world Analysis
por: Cain, Alexander R, et al.
Publicado: (2021) -
Description of Hospitalizations due to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Based on Vaccination Status
por: Moffa, Matthew A, et al.
Publicado: (2022) -
1476. Impact of an Educational Campaign on Rates of Sputum Culture Acquisition as an Opportunity for Antibiotic De-escalation
por: Snawerdt, Jessica, et al.
Publicado: (2020)